查阅近十年相关文献,对丹参制剂与心脑血管、抗肿瘤化学药联合用药的药动学研究进行整理分析和归纳总结。结果显示,丹参制剂对一些心脑血管和抗癌化学药的大鼠体内药动学参数会产生显著影响,如显著提高降脂药阿伐他丁、匹伐他丁和瑞伐他丁的血药浓度;显著提高抗癌药甲氨蝶呤和阿霉素的血药浓度或延长体内消除;分析整理文献,建议丹参制剂与抗血小板聚集药联合用药要慎重。联合用药时应关注其安全性、适当调整剂量,今后需要进一步开展基于代谢酶和转运体介导的药动学机制研究。 Check the relevant literature for nearly a decade, the pharmacokinetics study of Salviae miltiorrhizae preparations combined with cardiovascular and antineoplastic agents were analyzed and summarized. The results showed that Salvia miltiorrhiza preparations in some cardiovascular and anti-cancer drugs in rats pharmacokinetic parameters will have a significant impact, such as significantly lowering lipid-lowering drugs such as atorvastatin, pitavastatin and revastatin blood Drug concentration; significant increase in anticancer drugs methotrexate and doxorubicin plasma concentration or prolong in vivo elimination; analysis and collation of the literature, it is recommended Danshen formulations and anti-platelet aggregation drug combination should be careful. The combination should pay attention to its safety, appropriate dose adjustment, the future need to further carry out based on metabolic enzyme and transporter-mediated pharmacokinetic mechanisms.